TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00974935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide
Description: Single dose of recombinant staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.01, 0.1, 0.5, 2.5, 10 or 20 mcg intramuscular and 2 doses of 20 mcg intramuscular 21 days apart. STEBVax vaccine will be administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the non-dominant arm; subjects in the 2 dose cohort will have the vaccine administered in the alternate arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide
Description: Single dose of recombinant staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.01, 0.1, 0.5, 2.5, 10 or 20 mcg intramuscular and 2 doses of 20 mcg intramuscular 21 days apart. STEBVax vaccine will be administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the non-dominant arm; subjects in the 2 dose cohort will have the vaccine administered in the alternate arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide
Description: Single dose of recombinant staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.01, 0.1, 0.5, 2.5, 10 or 20 mcg intramuscular and 2 doses of 20 mcg intramuscular 21 days apart. STEBVax vaccine will be administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the non-dominant arm; subjects in the 2 dose cohort will have the vaccine administered in the alternate arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide
Description: Single dose of recombinant staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.01, 0.1, 0.5, 2.5, 10 or 20 mcg intramuscular and 2 doses of 20 mcg intramuscular 21 days apart. STEBVax vaccine will be administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the non-dominant arm; subjects in the 2 dose cohort will have the vaccine administered in the alternate arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide
Description: Single dose of recombinant staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.01, 0.1, 0.5, 2.5, 10 or 20 mcg intramuscular and 2 doses of 20 mcg intramuscular 21 days apart. STEBVax vaccine will be administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the non-dominant arm; subjects in the 2 dose cohort will have the vaccine administered in the alternate arm.
Study: NCT03618550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal doxorubicin
Description: 15mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal doxorubicin
Description: 15mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal doxorubicin
Description: 15mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal doxorubicin
Description: 15mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell mobilization and collection
Description: Stem cell mobilization and collection will be performed as per standard MSKCC guidelines after 2-4 cycles of pembrolizumab-GVD.
Study: NCT00974935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide
Description: Single dose of recombinant staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.01, 0.1, 0.5, 2.5, 10 or 20 mcg intramuscular and 2 doses of 20 mcg intramuscular 21 days apart. STEBVax vaccine will be administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the non-dominant arm; subjects in the 2 dose cohort will have the vaccine administered in the alternate arm.
Study: NCT03618550

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell mobilization and collection
Description: Stem cell mobilization and collection will be performed as per standard MSKCC guidelines after 2-4 cycles of pembrolizumab-GVD.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell mobilization and collection
Description: Stem cell mobilization and collection will be performed as per standard MSKCC guidelines after 2-4 cycles of pembrolizumab-GVD.
Study: NCT00974935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide
Description: Single dose of recombinant staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.01, 0.1, 0.5, 2.5, 10 or 20 mcg intramuscular and 2 doses of 20 mcg intramuscular 21 days apart. STEBVax vaccine will be administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the non-dominant arm; subjects in the 2 dose cohort will have the vaccine administered in the alternate arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STEBVax vaccine
Description: Single dose of recombinant staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.01, 0.1, 0.5, 2.5, 10 or 20 mcg intramuscular and 2 doses of 20 mcg intramuscular 21 days apart. STEBVax vaccine will be administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the non-dominant arm; subjects in the 2 dose cohort will have the vaccine administered in the alternate arm.
Study: NCT03316560

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV2tYF-GRK1-RPGR
Description: Adeno-associated virus vector expressing a human RPGR gene

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV2tYF-GRK1-RPGR
Description: Adeno-associated virus vector expressing a human RPGR gene

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV2tYF-GRK1-RPGR
Description: Adeno-associated virus vector expressing a human RPGR gene

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV2tYF-GRK1-RPGR
Description: Adeno-associated virus vector expressing a human RPGR gene
Study: NCT01558570

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: One time blood draw
Study: NCT06248528

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver resection
Description: Patients in the intervention group received liver resection and postoperative adjuvant therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Locoregional therapy
Description: Patients in the control group received locoregional therapy and systemic therapy
Study: NCT03618550

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell mobilization and collection
Description: Stem cell mobilization and collection will be performed as per standard MSKCC guidelines after 2-4 cycles of pembrolizumab-GVD.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell mobilization and collection
Description: Stem cell mobilization and collection will be performed as per standard MSKCC guidelines after 2-4 cycles of pembrolizumab-GVD.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell mobilization and collection
Description: Stem cell mobilization and collection will be performed as per standard MSKCC guidelines after 2-4 cycles of pembrolizumab-GVD.
Study: NCT02863263

Intervention type: DEVICE
Group type: OTHER
Intervention: Foam Dressing
Description: The purpose of the study is not to compare between the 2 devices, but to determine the efficacy of each type of device on its own. Subjects are randomised to one of 2 arms.

Intervention type: DEVICE
Group type: OTHER
Intervention: Foam Dressing with Povidone Iodine
Description: The purpose of the study is not to compare between the 2 devices, but to determine the efficacy of each type of device own. Subjects are randomised to one of 2 arms.
Study: NCT00559338

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant B-type, natriuretic peptide
Description: The intravenous infusion of nesiritide consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The nesiritide was mixed in 250 ml of 0.9% normal saline solution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The intravenous infusion of placebo consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The placebo was mixed in 250 ml of 0.9% normal saline solution.
Study: NCT04113629

Intervention type: DEVICE
Group type: OTHER
Intervention: HCV point of care machine
Description: Xpert HCV Assay performed on the GeneXpert point of care machine
Study: NCT03012789

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery
Description: Surgical excision
Study: NCT03106519

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposome bupivacaine + bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome bupivacaine + bupivacaine
Study: NCT00306904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevasiranib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevasiranib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevasiranib
Study: NCT01427335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcium
Description: intravenous infusion of 10 % calcium gluconate 10 mL in 200 mL of physiologic saline on the day of ovum pickup, day 1,day 2, and day 3 after ovum pickup were administered in study group.~Intravenous infusion was performed within 30 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9 % saline
Description: 0.9 % saline intravenous infusion
Study: NCT00183443

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Divalproex-extended release (DVP-ER)
Description: Divalproex ER will be given in 250 mg or 500 mg tablets. Dosing is once a day, every day, for the duration of study participation, either 12 or 26 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Divalproex-extended release (DVP-ER)
Description: Divalproex ER will be given in 250 mg or 500 mg tablets. Dosing is once a day, every day, for the duration of study participation, either 12 or 26 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Divalproex-extended release (DVP-ER)
Description: Divalproex ER will be given in 250 mg or 500 mg tablets. Dosing is once a day, every day, for the duration of study participation, either 12 or 26 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium
Description: Extended release lithium will be provided in 300 mg capsules. Participants will be dosed to a therapeutic blood level of lithium from 0.8 to 1.2 mcg/L.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: Quetiapine will be dosed to efficacy, provided in 50 mg, 100 mg, 200 mg, or 300 mg pills.
Study: NCT02640976

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human menopausal gonadotrophin (HMG)
Description: \[Merional® 75 IU ampoules, IBSA institut\]

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human menopausal gonadotrophin (HMG)
Description: \[Merional® 75 IU ampoules, IBSA institut\]

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH antagonist Cetrorelix
Description: \[Cetrotide® 0.25 mg syringes, Merck Serono\]

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH antagonist Cetrorelix
Description: \[Cetrotide® 0.25 mg syringes, Merck Serono\]

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human chorionic gonadotrophin (hCG)
Description: \[Choriomon® 5000 IU ampoules, IBSA institut\]

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human chorionic gonadotrophin (hCG)
Description: \[Choriomon® 5000 IU ampoules, IBSA institut\]
Study: NCT02364817

Intervention type: BEHAVIORAL
Intervention: cognitive and psychiatric assessment
Description: Administered at baseline:~* Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar)~* hyperactivity : Adult ADHD Self-Report Scale (ASRS), Wenders-Utah Rating Scale (WURS), Diagnostic Interview for Adult ADHD 2nd edition (DIVA 2.0)~* psychiatric history : Mini International Neuropsychiatric Interview 5th edition (MINI 5.0), Personality Disorder Questionnaire for the DSM-IV (PDQ-4)~* cognitive functions : Frontal Assessment Battery (FAB), Montreal Cognitive Assessment (MoCA)~* impulsivity : Barratt's Impulsiveness scale 11th edition (BIS-11)~* alcohol consumption: alcohol - timeline follow-back (A-TLFB) ,administered at baseline (month before hospitalization), week 4 visit, week 6 visit, and week 12 visit.~* administered at week 12: ASRS
Study: NCT00679107

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of OP-1 Putty in Uninstrumented posterolateral fusion
Description: Use of OP-1 Putty in Uninstrumented posterolateral fusion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Use of OP-1 Putty in Uninstrumented posterolateral fusion
Description: Use of OP-1 Putty in Uninstrumented posterolateral fusion
Study: NCT05057351

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isopentenyltheophylline 0.44% + Glycerin 4.56%
Description: Application of topical cream twice a day on the area affected by Atopic Dermatitis

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Glycerin 4.56%
Description: Application of topical cream twice a day on the area affected by Atopic Dermatitis
Study: NCT01586728

Intervention type: OTHER
Group type: OTHER
Intervention: Air - oxygen
Description: 1. his routine long term treatment without nocturnal oxygen therapy during 6 weeks (air period)~2. nocturnal oxygen therapy with a stable flow to obtain a nocturnal SpO2 \> 90% (oxygen period) while continuing his routine long term treatment during 6 weeks.~During the oxygen period, the oxygen flow will be at least 1.5l/min. This flow may be increased up to 2L/min in case of the presence of nocturnal periods with SpO2 \<= 90%.

Intervention type: OTHER
Group type: OTHER
Intervention: Oxygen - Air
Description: 1. nocturnal oxygen therapy with a stable flow to obtain a nocturnal SpO2 \> 90% (oxygen period) while continuing his routine long term treatment during 6 weeks.~2. his routine long term treatment without nocturnal oxygen therapy during 6 weeks (air period) During the oxygen period, the oxygen flow will be at least 1.5l/min. This flow may be increased up to 2L/min in case of the presence of nocturnal periods with SpO2 \<= 90%.
Study: NCT02514538

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non- effervescent Paracetamol kern
Description: 1g

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non- effervescent Paracetamol kern
Description: 1g

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Effervescent paracetamol termalgin
Description: 1 g

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Effervescent paracetamol termalgin
Description: 1 g
Study: NCT01756157

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CINRYZE with rHuPH20

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CINRYZE with rHuPH20
Study: NCT02860793

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bone marrow aspiration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Study: NCT04063943

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sidus Stem-Free Shoulder
Description: Device: Sidus Stem-Free Total Shoulder Arthroplasty System
Study: NCT01733563

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Soft drink consumption

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Soft drink consumption

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Soft drink consumption

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Soft drink consumption
Study: NCT01123889

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: platelet rich plasma injection
Description: 45 ml of a patient's own blood will be collected via blood draw, maintaining sterile technique. This will then be spun down using a Magellan Autologous Platelet Separator System, yielding platelet rich plasma (PRP). Under sterile conditions, patients will receive a 5 cc PRP injection (consisting of their own PRP) with 1 cc of 1% lidocaine and 1 cc of 0.5% ropivacaine into the subacromial space, administered by an orthopedic surgeon. This will be done using a posterior lateral approach. The patient will be monitored for 10 minutes in clinic for adverse reactions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroid injection
Description: Under sterile conditions, patients will receive a 5cc injection consisting of 2cc 1% lidocaine, 2cc 0.5% ropivacaine, and 1cc kenalog corticosteroid (40mg/cc) into the subacromial space utilizing a posterior lateral approach. Patients will be observed for 10 min in clinic for any adverse reactions.
Study: NCT00537719

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK716155
Description: albiglutide subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo injection
Study: NCT01896232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Description: Administered intravenously three times per week. The starting dose was 5 mg, titrated up to 15 mg based on serum PTH and corrected calcium levels.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cinacalcet
Description: Cinacalcet was administered orally once a day. The starting dose was 30 mg daily, titrated up to 180 mg daily based on serum PTH and corrected calcium levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Placebo
Description: Administered orally once a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Placebo
Description: Administered intravenously (IV) three times per week.
Study: NCT00714142

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 62Cu-ethylglyoxal bis(thiosemicarbazone)
Description: 15-25 mCi, IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 62Cu-ethylglyoxal bis(thiosemicarbazone)
Description: 15-25 mCi, IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 62Cu-ethylglyoxal bis(thiosemicarbazone)
Description: 15-25 mCi, IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 15O-water
Description: 10-20 mCi, IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 15O-water
Description: 10-20 mCi, IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 15O-water
Description: 10-20 mCi, IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: PET Scan
Study: NCT04334785

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cryo-ablation
Description: Under the guide of ultrasound, cryo-ablation for the lump of early invasive breast cancer will be conducted.
Study: NCT01449721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous fluid
Description: 0.9% Sodium chloride intravenous fluid
Study: NCT03587350

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shimmer monitoring
Description: The shimmer monitor, monitors movement and the range of movement.
Study: NCT04265443

Intervention type: DEVICE
Intervention: Percutaneous coronary intervention
Description: PCI was performed using 2nd generation DES
Study: NCT03490903

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Subjects undergoing the Virtual Reality Intervention will be fitted with a VR headset and headphones, and undergo an immersive meditation experience provided by AppliedVR, Inc. The headphones will not be noise-cancelling, and the subject will be able to communicate with the physician or circulating nurse if needed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Injection
Description: Fentanyl is commonly administered to treat pain during invasive procedures such as coronary angiography. Intravenous fentanyl injection dosages are determined by the physician operator, and administered by the circulating nurse.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Injection
Description: Fentanyl is commonly administered to treat pain during invasive procedures such as coronary angiography. Intravenous fentanyl injection dosages are determined by the physician operator, and administered by the circulating nurse.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam injection
Description: Midazolam is commonly administered to treat anxiety during invasive procedures such as coronary angiography. Intravenous midazolam injection dosages are determined by the physician operator, and administered by the circulating nurse.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam injection
Description: Midazolam is commonly administered to treat anxiety during invasive procedures such as coronary angiography. Intravenous midazolam injection dosages are determined by the physician operator, and administered by the circulating nurse.
Study: NCT00188318

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hyperfractionated accelerated radiotherapy
Study: NCT00865111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion 150 mg Extended-Released Tablet, single dose
Description: A: Experimental Subjects received Abrika formulated products under fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Wellbutrin SR® 150 mg Sustained-Release Tablet, single dose
Description: B: Active comparator Subjects received GlaxoSmithKline formulated products under fasting conditions
Study: NCT01139905

Intervention type: OTHER
Group type: OTHER
Intervention: lopinavir/ritonavir
Description: standard dose of lopinavir/ritonavir 100/25 mg tablet q 12 hour.
Study: NCT01216982

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lovaza, omega-3 fatty acid ethyl ester
Description: Three 1g capsules/day for three months; this corresponds to a total of 2520mg EPA+DHA/day
Study: NCT02399800

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Celiac Block with triamcinolone and bupivicaine
Description: Endosonography of the pancreas performed following by analgesic injection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No Celiac Block
Description: EUS but no celiac block performed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra Plexus Triamcinolone and Bupivicaine Injection
Description: Injection of Triamcinolone and Bupivicaine into celiac plexus for pain relief
Study: NCT02077699

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei DG
Description: Lactobacillus casei DG (24 billion of live cells per pill) - 2 pills b.i.d. for 4 weeks
Study: NCT03727867

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
Description: Oral EGFR TKI begins on day 1 and continues until disease progresses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
Description: Oral EGFR TKI begins on day 1 and continues until disease progresses.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Participants were given Stereotactic Body Radiation Therapy in a dose of 60 Gy/8 fraction for the central tumor or 50 Gy/5 fraction for the peripheral lung cancer, respectively.